Adcetris
An intravenous targeted therapy used to treat Hodgkin lymphoma and certain T-cell lymphomas.
Where Brentuximab Vedotin is approved
All regulators →Of the three regulators tracked here, the first to approve Brentuximab Vedotin was the US, on 19 Aug 2011. It is approved in 3 of the 3 regulators tracked here.
- 1 EU orphan designation, most recently for treatment of cutaneous T-cell lymphoma (11 Jan 2012, withdrawn)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Brentuximab Vedotin
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Brentuximab Vedotin works
All drug targets →- Tubulin inhibitor InhibitorTarget: TubulinChEMBL only
- Tumor necrosis factor receptor superfamily member 8 binding agent Binding agentTarget: TNFRSF8 TNF receptor superfamily member 8✓ In ChEMBL and the Guide to Pharmacology
- T-cell non-Hodgkin lymphomaPhase 3
- Classic Hodgkin lymphomaPhase 3
- Diffuse large B-cell lymphomaPhase 3
- Mature T-cell and NK-cell non-Hodgkin lymphomaPhase 3
- Mycosis fungoidesPhase 3
- Primary cutaneous T-cell non-Hodgkin lymphomaPhase 3
- Lymphomatoid PapulosisPhase 2
- Sezary syndromePhase 2
- Adult T-cell leukemia/lymphomaPhase 2
- Diffuse sclerodermaPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1742994, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3), ligand 6772, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Brentuximab Vedotin
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 7 technology appraisals of Brentuximab Vedotin. 6 are current, and 6 of these recommend it for at least some patients. 1 older appraisal was replaced or withdrawn.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Brentuximab vedotin in combination for untreated stage 3 or 4 CD30-positive Hodgkin lymphoma NICE TA1059 | Recommended | 7 May 2025 | Current |
| Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma NICE TA641 | Recommended | 12 Aug 2020 | Current |
| Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma NICE TA577 | Optimised | 24 Apr 2019 | Current |
| Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma NICE TA524 | Optimised | 13 Jun 2018 | Current |
| Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma NICE TA478 | Optimised | 4 Oct 2017 | Current |
| Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma NICE TA446 | Optimised Optimised (Cancer Drugs Fund) | 28 Jun 2017 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Brentuximab Vedotin
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 1 product on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: AdcetrisEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Brentuximab Vedotin
- ATC code
- L01XC12
- ChEMBL
- CHEMBL1742994
- DrugBank
- DB08870
- CAS number
- 914088-09-8
- FDA UNII
- 7XL5ISS668
- Wikidata
- Q422324
- Wikipedia
- Brentuximab vedotin
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
What Adcetris is used for
ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine ( 1.1 ). • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide ( 1.2 ). • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation ( 1.3 ). • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates ( 1.4 ). • Adult patients with previou…
How it works
12.1 Mechanism of Action CD30 is a member of the tumor necrosis factor receptor family and is expressed on the surface of sALCL cells and on Hodgkin Reed-Sternberg (HRS) cells in cHL. CD30 is variably expressed in other T-cell lymphomas. Expression of CD30 on healthy tissue and cells is limited. In vitro data suggest that signaling through CD30-CD30L binding may affect cell survival and proliferation. Brentuximab vedotin is an antibody-drug conjugate (ADC). The antibody is a chimeric IgG1 directed against CD30. The small molecule, MMAE, is a microtubule-disrupting agent. MMAE is covalently attached to the antibody via a linker. Nonclinical data suggest that the anticancer activity of ADCETR…
Related clinical trials recruiting now
Explore more
How this page is built
The facts on this page are pulled directly from official U.S. FDA datasets — they are not written from memory. Each field below names the dataset it came from, so you can check it yourself.
- FDA Drug Label (openFDA) ↗ Indications, mechanism of action and pharmacologic class
- Drugs@FDA ↗ First FDA approval date and the company holding the application
- FDA Drug Shortage Database ↗ Current US supply / shortage status
Plain-English summaries and drug-class explainers are written and reviewed by Sreepriya Prasannan (MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany). Data is retrieved automatically from the sources above and cross-checked with AI-assisted verification (Anthropic's Claude) — brand and generic names are matched against the exact FDA product record so that a combination product or a different formulation cannot be mistaken for the drug on this page. An editor reviews the result before publication. We describe this in full in our editorial standards and corrections policy. The FDA data on this page was last retrieved on 5 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.